Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 327

1.

Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.

Stobaugh DJ, Deepak P, Ehrenpreis ED.

J Am Acad Dermatol. 2013 Sep;69(3):393-8. doi: 10.1016/j.jaad.2013.04.031. Epub 2013 May 14.

PMID:
23683730
2.

Possible association between isotretinoin and inflammatory bowel disease.

Reddy D, Siegel CA, Sands BE, Kane S.

Am J Gastroenterol. 2006 Jul;101(7):1569-73.

PMID:
16863562
3.

Concomitant antibiotic usage does not augment the risk of inflammatory bowel disease with isotretinoin treatment for acne: a review of the Food and Drug Administration Adverse Event Reporting System.

Stobaugh DJ, Deepak P, Ehrenpreis ED.

Eur J Clin Pharmacol. 2013 Apr;69(4):1041-2. doi: 10.1007/s00228-012-1416-1. Epub 2012 Oct 6. Review. No abstract available.

PMID:
23052415
4.

Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System.

Deepak P, Stobaugh DJ, Sherid M, Sifuentes H, Ehrenpreis ED.

Aliment Pharmacol Ther. 2013 Aug;38(4):388-96. doi: 10.1111/apt.12385. Epub 2013 Jun 26.

5.

Isotretinoin and inflammatory bowel disease: trial lawyer misuse of science and FDA warnings.

Tenner S.

Am J Gastroenterol. 2014 Apr;109(4):570-1. doi: 10.1038/ajg.2014.34.

PMID:
24698863
6.
7.

Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.

Johann-Liang R, Wyeth J, Chen M, Cope JU.

Pharmacoepidemiol Drug Saf. 2009 Jan;18(1):24-7. doi: 10.1002/pds.1679.

PMID:
19009550
8.

Isotretinoin updates.

On SC, Zeichner J.

Dermatol Ther. 2013 Sep-Oct;26(5):377-89. doi: 10.1111/dth.12084.

PMID:
24099068
10.

Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.

Alhusayen RO, Juurlink DN, Mamdani MM, Morrow RL, Shear NH, Dormuth CR; Canadian Drug Safety and Effectiveness Research Network.

J Invest Dermatol. 2013 Apr;133(4):907-12. doi: 10.1038/jid.2012.387. Epub 2012 Oct 25.

11.

Managing nonteratogenic adverse reactions to isotretinoin treatment for acne vulgaris.

Reilly BK, Ritsema TS.

JAAPA. 2015 Jul;28(7):34-9. doi: 10.1097/01.JAA.0000459815.24908.02. Review.

PMID:
26107793
12.

Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study.

Bernstein CN, Nugent Z, Longobardi T, Blanchard JF.

Am J Gastroenterol. 2009 Nov;104(11):2774-8. doi: 10.1038/ajg.2009.417. Epub 2009 Jul 21.

PMID:
19623167
13.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.

MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.

14.

Acne treatment and inflammatory bowel disease: what is the evidence?

Alikhan A, Henderson GP, Becker L, Sciallis GF.

J Am Acad Dermatol. 2011 Sep;65(3):650-4. doi: 10.1016/j.jaad.2011.04.016. Epub 2011 Jun 24. No abstract available.

PMID:
21704420
15.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.

PMID:
23032984
16.

Isotretinoin exposure and risk of inflammatory bowel disease.

Rashtak S, Khaleghi S, Pittelkow MR, Larson JJ, Lahr BD, Murray JA.

JAMA Dermatol. 2014 Dec;150(12):1322-6.

PMID:
25207875
17.

Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.

Deepak P, Stobaugh DJ.

Aliment Pharmacol Ther. 2014 Nov;40(9):1035-43. doi: 10.1111/apt.12936. Epub 2014 Aug 28.

18.

Isotretinoin-induced inflammatory bowel disease.

Passier JL, Srivastava N, van Puijenbroek EP.

Neth J Med. 2006 Feb;64(2):52-4.

19.

Isotretinoin use and the risk of inflammatory bowel disease: a case-control study.

Crockett SD, Porter CQ, Martin CF, Sandler RS, Kappelman MD.

Am J Gastroenterol. 2010 Sep;105(9):1986-93. doi: 10.1038/ajg.2010.124. Epub 2010 Mar 30.

20.

Isotretinoin use and the risk of inflammatory bowel disease.

Thakrar BT, Robinson NJ.

Am J Gastroenterol. 2011 May;106(5):1000-2; author reply 1002-3. doi: 10.1038/ajg.2011.28. No abstract available.

PMID:
21540903

Supplemental Content

Support Center